2025 Third Quarter Financial Results Our Mission: Protect and Save Lives October 29, 2025 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and ear ...

Core Viewpoint - Emergent BioSolutions Inc. has received a $30 million contract modification from BARDA to supply the CYFENDUS anthrax vaccine, with deliveries expected to start this year and conclude by March 2026 [1][2]. Group 1: Contract Details - The new contract modification is part of an ongoing collaboration with the U.S. government to ensure the availability of medical countermeasures against anthrax [2]. - This follows a previous contract modification of $50 million announced in December 2024 for the same vaccine [3]. Group 2: Product Information - CYFENDUS is indicated for post-exposure prophylaxis of anthrax disease in individuals aged 18 to 65 when administered with recommended antibacterial drugs [4]. - The vaccine was approved by the U.S. FDA in July 2023 for post-exposure use [2]. Group 3: Safety and Efficacy - The efficacy of CYFENDUS for post-exposure prophylaxis is based on studies in animal models of inhalational anthrax [4]. - Important safety information includes contraindications for individuals with a history of severe allergic reactions to the vaccine or its components [5].